Form SC 13D Sarepta Therapeutics, Filed by: Barry Richard
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 falls from record high as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Baird Upgrades Sarepta Therapeutic (SRPT) to Outperform; Favorable Risk/Reward
May 6, 2015 6:10 AM EDTBaird upgraded Sarepta Therapeutic (NASDAQ: SRPT) from Neutral to Outperform with a price target of $20.00 (from $16.00), citing favorable risk/reward into FDA guidance.
Analyst Brian Skorney commented, "We're jumping back into the stock after last week's NDA submission by potential competitor... More
Sarepta Therapeutics (SRPT) New Board Member Rick Barry Files 13D
May 5, 2015 3:50 PM EDTSarepta Therapeutics (NASDAQ: SRPT) is active after Rick Barry filed a 13D showing a 7.66% stake, or 3,165,014. Rick Barry has been nominated to join the Board of Directors of the Issuer, Sarepta Therapeutics, and has accepted the nomination.
SI NOTE: Barry has been a... More
